Anakinra Market Anticipated To Witness Robust Growth, Surpassing 8.8 Billion By 2029

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current Anakinra Market Size and Its Estimated Growth Rate?
The market for anakinra has expanded dramatically in the past few years. It is forecasted to escalate from $4.89 billion in 2024 to $5.51 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.8%. The growth witnessed in the historical period is due to factors such as an increased incidence of rheumatoid arthritis, receipt of approval for using anakinra in rare autoinflammatory disorders like NOMID, heightened understanding of biologics in the treatment of chronic inflammation, and amplified use of targeted therapies.

In the coming years, the anakinra market is anticipated to witness significant expansion, projecting a size of $8.81 billion by 2029 with a compound annual growth rate (CAGR) of 12.4%. The growth for the said period is likely to be driven by the broadening spectrum of indications for anakinra in various conditions, an increased emphasis on tailored medicine, escalating occurrence of unique autoinflammatory disorders, improvements in medication delivery systems, and expanding access to healthcare in developing markets, which is fuelling the demand for biologics. Key trends predicted for the forecast period involve the creation of biosimilars and next-generation IL-1 inhibitors, the preference for home-based and self-administered treatments, partnerships between biotechnology firms and academic institutions, and the use of digital health methods to encourage patient compliance.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21095

How Are Emerging Segments Shaping the Anakinra Market Landscape?
The anakinra market covered in this report is segmented -

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies
3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:
1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease
2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease
3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms
4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares
5) By Adult-Onset Still's Disease: Active Disease, Remission Induction
6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management
7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

Which Growth Factors Are Influencing Anakinra Market Expansion?
The growth of the anakinra market is anticipated to be spurred by the increasing prevalence of autoimmune disorders. Autoimmune disorders arise when the body's immune system mistakenly attacks its own healthy tissues and organs, perceiving them as external threats. Genetic susceptibility and environmental triggers such as infections, pollution, and changes in diet are contributing to the heightened incidence of these disorders. Anakinra is used for the treatment of autoimmune disorders as it inhibits interleukin-1 (IL-1) activity, diminishing inflammation associated with diseases like rheumatoid arthritis, Still's disease, and periodic fever syndromes. For example, a report by the Australian Institute of Health and Welfare, an Australian government organization, stated in June 2024 that the rate of hospitalizations for rheumatoid arthritis in 2021-22 was 39 per 100,000 population, equating to 10,000 hospitalizations, a spike of 25% from the previous year's 8,000. Hence, the augmented prevalence of autoimmune disorders is fueling the expansion of the anakinra market. The Influence Of Escalating Healthcare Costs On Market Expansion

Who Are the Dominant Players Across Different Anakinra Market Segments?
Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

What Are the Major Trends Shaping the Anakinra Market?
Leading businesses in the Anakinra market are getting the green light from regulatory authorities to broaden its usage for new therapeutic practices. Such authorizations come from government bodies that assess the safety, effectiveness, and quality of a drug before allowing its promotion and prescription for certain health conditions. For example, in November 2022, the US-based Food and Drug Administration permitted the Emergency Use Authorization (EUA) for Kineret, a formulation of anakinra, to be used for adult COVID-19 patients with related pneumonia who require additional oxygen. The goal here is to curtail the risks of severe respiratory failure. This approval was based on the results of the SAVE-MORE phase 3 trial that revealed early intervention with Kineret improved patient conditions. Kineret acts by suppressing cytokines IL-1α and IL-1β, which are linked with extreme inflammatory response in severe COVID-19 cases. While it still hasn't received full FDA approval for this indication, it is allowed for temporary usage during the prevailing public health crisis.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

Which Geographic Regions Are Expected to Dominate the Anakinra Market in the Coming Years?
North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Anakinra Market?
2. What is the CAGR expected in the Anakinra Market?
3. What Are the Key Innovations Transforming the Anakinra Industry?
4. Which Region Is Leading the Anakinra Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.